Related Experiment Video

Updated: Jun 23, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

The MINDACT trial: the first prospective clinical validation of a genomic tool

Fatima Cardoso1, Martine Piccart-Gebhart, Laura Van't Veer

  • 1Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium. fatima.cardoso@bordet.be

Molecular Oncology
|April 23, 2009
PubMed

Insights

Accurately identifying patients needing adjuvant treatment is crucial in oncology. The MINDACT trial validates MammaPrint, an RNA-based tool, to personalize cancer therapy and avoid unnecessary chemotherapy.

Area of Science:

  • Oncology
  • Genomics
  • Personalized Medicine

Background:

  • Distinguishing patients who need adjuvant therapy is a major challenge in oncology.
  • Personalized medicine aims to tailor treatments to individual patients and tumor characteristics.

Purpose of the Study:

  • To prospectively validate the performance of the MammaPrint 70-gene expression profile.
  • To assess the utility of MammaPrint in guiding adjuvant treatment decisions for early-stage breast cancer patients.

Main Methods:

  • The MINDACT trial is a prospective, randomized study.
  • It compares treatment decisions based on clinical-pathological information alone versus clinical-pathological information plus MammaPrint results.

Main Results:

  • The study aims to demonstrate the superiority of MammaPrint in identifying patients who can safely avoid chemotherapy.
  • Results will inform clinical practice regarding the use of genomic tools in adjuvant therapy decisions.

Conclusions:

  • Validation of MammaPrint could significantly impact adjuvant treatment strategies in early breast cancer.
  • This approach supports personalized medicine by optimizing therapy selection and reducing overtreatment.

More Related Videos

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...